# AstraZeneca Plc  US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-us-fda-grants-lynparza-orphan-drug-designation-for-pancreatic-cancer/412759965
- Published: 2018-10-16T07:42:02+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US 
and Canada) announced that they were granted orphan drug designation (ODD) by the
US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment 
of pancreatic cancer.

Pancreatic cancer is a rare, life-threatening disease that accounts for about 3%
of all cancers in the US.i Due to the late onset of symptoms, patients are often
diagnosed after the cancer has progressed to locally advanced or metastatic stages
of the disease.ii Five-year survival rates remain low in the US at 8.5%.iii

> **Sean Bohen, Executive Vice President, Global Medicines Development and Chief
> Medical Officer said:** “Pancreatic cancer is an area of significant unmet medical
> need. This is especially true for patients with metastatic disease where the benefits
> of current treatment options are very limited.”
> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, at MSD Research Laboratories, said**: “Pancreatic cancer is a
> relatively less common, but life-threatening, form of cancer. The FDA granting
> Orphan Drug Designation is a positive step for patients with pancreatic cancer
> and continues to reinforce the importance of our collaboration in bringing Lynparza
> to more patients in need.”

ODD status was granted for the treatment of ovarian cancer in October 2013. Earlier
this year an amended ODD status was granted to include both fallopian tube and primary
peritoneal cancers following the expanded US approval of Lynparza in August 2017
for the maintenance treatment of adult patients with recurrent epithelial ovarian,
fallopian tube or primary peritoneal cancer, who are in a complete or partial response
to platinum-based chemotherapy. The FDA grants ODD status to medicines intended 
for the treatment, diagnosis or prevention of rare diseases or disorders that affect
fewer than 200,000 people in the US.

The use of Lynparza in pancreatic cancer is being assessed in the ongoing Phase 
III POLO trial, which is testing Lynparza as maintenance monotherapy vs placebo 
in patients with germline BRCA-mutated metastatic pancreatic cancer whose disease
has not progressed following 1st-line platinum-based chemotherapy. Results from 
the POLO trial are expected in the first half of 2019.

**About the POLO Phase III trial**

POLO is a Phase III, randomised, double-blinded, placebo-controlled trial to evaluate
the efficacy and safety of Lynparza tablets (300 mg twice daily) as maintenance 
monotherapy compared with placebo, in patients with germline BRCA-mutated metastatic
pancreatic cancer whose disease has not progressed following 1st-line platinum-based
chemotherapy. The trial randomised 145 patients to receive Lynparza or placebo (
3:2). The primary endpoint is progression-free survival.

**About Lynparza**

Lynparza (olaparib) was the first in class PARP inhibitor and the first targeted
treatment to potentially exploit DNA damage response (DDR) pathway deficiencies,
such as BRCA mutations, to preferentially kill cancer cells. Specifically, in vitro
studies have shown that Lynparza-induced cytotoxicity may involve inhibition of 
PARP-enzymatic activity and increased formation of PARP-DNA complexes, resulting
in DNA damage and cancer cell death.

Lynparza, which has the broadest clinical development programme of any PARP inhibitor,
is being investigated in a range of DDR-deficient tumour types, and is the foundation
of AstraZeneca’s industry-leading portfolio of compounds targeting DDR mechanisms
in cancer cells.

**About the AstraZeneca and MSD Strategic Oncology Collaboration**

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD
outside the United States and Canada, announced a global strategic oncology collaboration
to co-develop and co-commercialise Lynparza, the world’s first PARP inhibitor and
potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. 
Working together, the companies will develop Lynparza and selumetinib in combination
with other potential new medicines and as monotherapies. Independently, the companies
will develop Lynparza and selumetinib in combination with their respective PD-L1
and PD-1 medicines.

**About AstraZeneca in Oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020 and a broad pipeline of small molecules and biologics in development, we
are committed to advance Oncology as a key growth driver focused on lung, ovarian,
breast and blood cancers. In addition to our core capabilities, we actively pursue
innovative partnerships and investments that accelerate the delivery of our strategy
as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

**About AstraZeneca**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the
discovery, development and commercialisation of prescription medicines, primarily
for the treatment of diseases in three therapy areas – Oncology, Cardiovascular,
Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and
its innovative medicines are used by millions of patients worldwide.

Share on:
